Neuren Pharmaceuticals Ltd (ASX: NEU) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Neuren Pharmaceuticals Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $2.65 billion
P/E Ratio 16.85
Dividend Yield 0.00%
Shares Outstanding 129.75 million
Earnings per share 1.201
Dividend per share N/A
Year To Date Return -18.94%
Earnings Yield 5.93%
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Neuren Pharmaceuticals Ltd (ASX: NEU)
    Latest News

    A woman sits back and enjoys the view from a paraglider, indicating share price lifts for ASX travel and adventure shares
    Investing Strategies

    Top-performing ASX 200 shares of 2023 without stomach-churning volatility

    Who said losing sleep from violent price changes was necessary to beat the market?

    Read more »

    a man sits on a ridge high above a large city full of high rise buildings as though he is thinking, contemplating the vista below.
    Share Market News

    Best ASX 200 shares vs. best suburbs for property investment in 2023

    Based on capital growth, these were the best performing ASX 200 shares and suburban property markets of 2023.

    Read more »

    Five people in an office high five each other.
    Best Shares

    5 best performing ASX All Ords shares of 2023

    Based on capital growth, these are the best 5 ASX All Ords shares of 2023.

    Read more »

    Two people comparing and analysing material.
    Share Market News

    ASX 200 shares vs. property: Which delivered the best growth in 2023?

    You won't believe what happened.

    Read more »

    A bearded man holds both arms up diagonally and points with his index fingers to the sky with a thrilled look on his face over these rising Tassal share price
    Share Gainers

    Can you guess which were the best-performing ASX 200 shares in 2023?

    These shares made their shareholders smile during the past 12 months.

    Read more »

    A man wearing a white coat holds his hands up and mouth open with joy.
    Investing Strategies

    Could investing $10,000 in this ASX 200 share make you a millionaire?

    Turning $10k into seven figures could seem like magic, but stock investors can do it with thorough research and patience.

    Read more »

    Contented looking man leans back in his chair at his desk and smiles.
    Broker Notes

    Top brokers name 3 ASX shares to buy next week

    Brokers gave the thumbs up to these ASX shares last week. Why are they bullish?

    Read more »

    A person sitting at a desk smiling and looking at a computer.
    Share Gainers

    Why Boss Energy, Lynas, Neuren, and Ora Banda shares are rising today

    These ASX shares are ending the week strongly. But why?

    Read more »

    Three guys in shirts and ties give the thumbs down.
    Share Fallers

    Why Atlantic Lithium, KMD Brands, Neuren, and PEXA shares are falling today

    These ASX shares are taking a tumble on Wednesday.

    Read more »

    A female executive smiles as she carries out business on her mobile phone.
    Broker Notes

    Top brokers name 3 ASX shares to buy today

    Here's what brokers are recommending as buys this week.

    Read more »

    Mum playing with her baby boy holding him on her tummy as she lays down while smiling about the Bubs share price going up today
    Investing Strategies

    Could buying this ASX 200 stock at $23 be like investing in Amazon in 2008?

    One Australian company is going gangbusters at the moment, and its stock is already a 17-bagger over the past 5…

    Read more »

    A diverse group of happy office workers join hands in a team high five in celebration of a job well done.
    Share Gainers

    Why G8 Education, Lake Resources, Liontown, and Neuren shares are racing higher

    These ASX shares are having a strong session on Tuesday.

    Read more »

    Frequently Asked Questions

    No, Neuren Pharmaceuticals does not pay dividends at this time. 

    Neuren Pharmaceuticals Limited (ASX: NEU) listed on the ASX on 3 February 2005.

    NEU ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Neuren Pharmaceuticals Ltd

    Neuren Pharmaceuticals Limited (ASX: NEU) is a biopharmaceutical company specialising in developing new therapies for neurodevelopmental disorders that emerge in early childhood and are characterised by impaired connections and signalling between brain cells. 

    In March 2023, the US Food and Drug Administration approved DAYBUE™ (trofinetide) for the treatment of Rett syndrome in adults and children two years and older. Neuren's US partner Acadia Pharmaceuticals (NASDAQ: ACAD) holds a worldwide exclusive licence from Neuren for trofinetide. At this time, DAYBUE is the first and only drug approved for the treatment of Rett syndrome. Trofinetide has also demonstrated clinical benefit in a Phase 2 trial in treating Fragile X syndrome.

    Neuren's second product NNZ-2591 is currently in Phase 2 clinical trials for the treatment of Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome, and Prader-Willi syndrome. The drug candidate has shown positive effects in mouse models of each syndrome and was successful in a Phase 1 clinical trial. The number of patients across these four disorders is estimated as five times the number of Rett syndrome patients. There are currently no drugs approved for these conditions, apart from growth hormone to treat some aspects of Prader-Willi. 

    Acadia Pharmaceuticals also holds a worldwide exclusive licence to develop and commercialise NNZ-2591 for Rett syndrome and Fragile X syndrome. Neuren retains worldwide rights to NNZ-2591 in all other indications.

    NEU Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    27 Mar 2024 $20.77 $0.53 2.62% 304,897 $20.13 $20.77 $20.13
    26 Mar 2024 $20.24 $-0.29 -1.41% 174,834 $20.53 $20.53 $20.12
    25 Mar 2024 $20.53 $0.31 1.53% 384,754 $20.25 $20.53 $20.00
    22 Mar 2024 $20.22 $-0.54 -2.60% 398,261 $20.60 $20.68 $20.01
    21 Mar 2024 $20.76 $0.15 0.73% 424,157 $20.93 $21.40 $20.65
    20 Mar 2024 $20.61 $0.10 0.49% 354,523 $20.65 $21.07 $20.17
    19 Mar 2024 $20.51 $0.01 0.05% 348,441 $20.44 $20.74 $20.32
    18 Mar 2024 $20.50 $0.26 1.28% 359,169 $19.79 $20.61 $19.75
    15 Mar 2024 $20.24 $0.54 2.74% 791,791 $19.70 $20.25 $19.16
    14 Mar 2024 $19.70 $-0.93 -4.51% 489,213 $20.50 $20.76 $19.70
    13 Mar 2024 $20.63 $-0.50 -2.37% 419,228 $21.00 $21.34 $20.53
    12 Mar 2024 $21.13 $1.06 5.28% 792,521 $20.20 $21.25 $20.10
    11 Mar 2024 $20.07 $0.12 0.60% 370,323 $19.82 $20.42 $19.54
    08 Mar 2024 $19.95 $0.49 2.52% 744,590 $19.89 $20.45 $19.78
    07 Mar 2024 $19.46 $-0.30 -1.52% 917,532 $19.88 $19.90 $19.26
    06 Mar 2024 $19.76 $0.11 0.56% 560,310 $19.66 $20.17 $19.61
    05 Mar 2024 $19.65 $-0.03 -0.15% 530,636 $19.49 $19.80 $19.10
    04 Mar 2024 $19.68 $-0.03 -0.15% 362,082 $19.98 $20.19 $19.68
    01 Mar 2024 $19.71 $0.35 1.81% 842,519 $19.88 $20.48 $19.66
    29 Feb 2024 $19.36 $0.21 1.10% 914,234 $18.91 $19.70 $18.80
    28 Feb 2024 $19.15 $-2.33 -10.85% 2,584,344 $21.25 $21.26 $18.16
    27 Feb 2024 $21.48 $-0.36 -1.65% 469,030 $22.14 $22.46 $21.26

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    13 Sep 2023 Joseph(Joe) Basile Buy 5,000 $59,950
    On-market trade.
    14 Jun 2023 Trevor Scott Sell 1,175,000 $15,275,000
    On-market trade.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Dr Trevor D Scott Non-Executive Director Mar 2002
    Trevor joined the Neuren Board in 2002. He is the founder of T.D. Scott and Co., an accountancy and consulting firm, which he formed in 1988. He is an experienced advisor to companies across a variety of industries. Trevor serves on numerous corporate boards and is chairman of several.
    Ms Dianne Margaret Angus Non-Executive Director Jul 2018
    Dianne joined the Neuren Board in 2018. She has worked as a senior executive and non-executive director within
    the biotechnology, biopharmaceutical and agritech industries for over twenty-five years. She has created numerous
    global industry partnerships which include Prana Biotechnology, Gerolymatos International, Florigene, Suntory &
    Monsanto to yield novel and competitive medical, pharmaceutical and agricultural products. Dianne has successfully
    forged strong partnerships with key medical opinion leaders to create innovative clinical research programs and
    driven the development path for novel neurological pre-clinical agents to late-stage clinical assets before the FDA
    and European regulators. With over fifteen years experience in an ASX and NASDAQ listed company, she has expertise
    in business development, capital raising, investor relations, regulatory affairs and intellectual property, together
    with corporate governance and compliance capabilities. Dianne holds a Masters degree in biotechnology and is a
    registered patent attorney.
    Mr Jonathan (Jon) Charles Pilcher Chief Executive OfficerManaging Director Aug 2013
    Jon joined Neuren in 2013 as CFO and was appointed CEO in May 2020. He has played a central role in all aspects of Neuren s R&D, commercial and corporate activities. Before joining Neuren he was a member of the leadership team at Acrux (ASX: ACR) throughout a period that included Acruxs IPO and listing on the ASX, the development and FDA approval of three novel pharmaceutical products and a transforming licensing deal with Eli Lilly in 2010. He formerly spent seven years in a series of executive positions in the R&D and corporate functions of international pharmaceutical groups Medeva and Celltech, which are now part of UCB. Jon is a Chartered Accountant and holds a degree in Biotechnology from the University of Reading in the UK. He is a non executive director of BTC Health Limited (ASX: BTC).
    Dr Jenny Lee Harry Non-Executive Director Jul 2018
    Jenny joined the Neuren Board in 2018. She has 20 years experience in executive management of companies in the
    biotechnology and biopharmaceutical industry. Jenny is an accomplished CEO and Managing Director with experience
    in growing companies from start up to commercialisation. She has served on Boards of a number of listed and unlisted
    companies and is currently a Non Executive Director of Aeris Environmental Limited (ASX:AEI) and on the Boards IP
    sub-committee of the Childrens Medical Research Institute. Jenny is a graduate of the Harvard Business School General
    Manager Program and the Australian Institute of Company Directors.
    Mr Patrick Davies Non-Executive DirectorNon-Executive Chairman Jul 2018
    Patrick joined the Neuren Board in 2018. He has held executive management roles in the Australian and New Zealand healthcare industry for over twenty five years having performed successfully in senior roles across many industry sectors including pharmacy, primary care, pharmaceutical and consumer products. During his ten year period as Chief Executive Officer of EBOS Group Limited (and previously Symbion), the enterprise value of the group achieved compound annual growth in enterprise value of +20% (from circa $450M to in excess of $3.1B). He is a director on other corporate boards and provides strategic advice to a range of healthcare businesses and investors.
    Mr Joseph(Joe) Basile Non-Executive Director Mar 2023
    Mr Basile has held a number of executive roles in the pharmaceutical industry for over 30 years, most recently as Group CFO at iNova Pharmaceuticals based in Singapore and prior to that with Novartis in senior Finance leadership and Commercial Sales leadership roles in Australia and Asia. Joe has experience in corporate mergers and acquisitions, capital management and overseeing expansion activities .
    Ms Lauren Frazer Chief Financial OfficerCompany Secretary Aug 2020
    -
    Lauren Frazer Chief Financial OfficerCompany Secretary
    -
    LIZA SQUIRES, M.D. Chief Medical Officer
    -
    LARRY GLASS Chief Science Officer
    -
    VIRGINIE DUREZ Senior Director Product Development & Project Management
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    NATIONAL NOMINEES LIMITED 11,810,223 9.35%
    Citicorp Nominees Pty Limited 10,759,990 8.52%
    HSBC CUSTODY NOMINEES (AUSTRALIA) LIMITED 9,174,182 7.27%
    J P Morgan Nominees Australia Pty Limited 8,875,428 7.03%
    HSBC Custody Nominees (Australia) Limited A/C 2 6,639,176 5.26%
    Cameron Richard Pty Ltd 4,206,313 3.33%
    BNP Paribas Noms Pty Ltd 2,710,864 2.15%
    Stuart Andrew Pty Ltd 2,460,000 1.95%
    Essex Castle Limited 2,367,144 1.87%
    Smithley Super Pty Ltd 2,010,000 1.59%
    Linwierik Super Pty Ltd 1,885,000 1.49%
    Sharesies Nominee Limited 1,385,966 1.10%
    Mxb Investments Llc 1,330,000 1.05%
    Dr Trevor Scott 1,000,000 0.79%
    First Colbyco Pty Ltd 790,000 0.63%
    Mjhft Pty Ltd 750,000 0.59%
    Dr Robin Lance Congreve 671,637 0.53%
    Hobson Wealth Custodians Ltd 589,337 0.47%
    Emancipayte Pty Ltd 476,607 0.38%
    Bnp Paribas Nominees Pty Ltd Acf Clearstream 465,450 0.37%

    Profile

    since

    Note